Welcome to our dedicated page for International Flavors&Fragranc news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors&Fragranc stock.
International Flavors & Fragrances Inc. (NYSE: IFF) is a global leader in sensory experiences and specialty ingredients, serving industries from food technology to pharmaceutical solutions. This dedicated news hub provides investors and industry professionals with essential updates on IFF developments, including earnings reports, strategic partnerships, and scientific breakthroughs.
Key resources include: Quarterly financial results, innovation announcements in flavors/fragrances, bioscience advancements, and sustainability initiatives. Our curated collection ensures access to verified press releases and market analyses that impact IFF's position in the $120B+ specialty chemicals sector.
Bookmark this page for real-time updates on IFF's product launches, regulatory milestones, and leadership changes. Combine technical insights with strategic context to make informed decisions about this NYSE-listed innovator.
IFF (NYSE: IFF) has announced a significant expansion of its pet portfolio, introducing advanced biotechnology solutions for companion animal care. The company has launched new products including Microsource™ CA for cat litter management and Betafin® Pet for pet hydration and gut health.
The expansion is supported by specialized R&D centers including the Pet Translational Research Lab (Wilmington, DE), Pet Enzymes Lab (Brabrand, Denmark), and Pet Applications Lab (New Century, KS). The new portfolio features enzyme-driven palatability solutions, sustainable ingredients, and functional health technologies.
Microsource™ CA reduces fecal ammonia odors by four times within 7 days, while Betafin® Pet offers natural betaine for both dogs and cats. The portfolio also includes enzymes, probiotics, plant protein, food protection solutions, natural colors, and proprietary flavor technology.
IFF (NYSE: IFF) Pharma Solutions has announced its participation at Vitafoods™ Europe 2025, showcasing its plant-based dietary supplement ingredients portfolio. The event will take place May 20-22 at the Fira Barcelona Gran Via, booth 4F25.
The company will present several innovative brands including SeaGel®, VERDIGEL™ SC, GRINDSTED® Pectin Premium, Ac-Di-Sol®, Avicel®, Accelerate®, and METHOCEL™. These products offer solutions ranging from vegan softgels and plant-based gummies to tablet binders and disintegrants.
The showcase highlights IFF's commitment to advancing the dietary supplement industry through high-performance, plant-based ingredients and reliable technologies for immediate and controlled release applications.
IFF (NYSE: IFF) has inaugurated its Scent Dubai Creative Center, a 2,000-square-meter facility at the Dubai Science Park Laboratory Complex. The center aims to strengthen IFF's presence in the Middle East's perfumery market, which is projected to reach $7 billion by 2034.
The state-of-the-art facility features a perfumery art studio for customer co-creation, a traditional Middle Eastern majlis, and an academy for perfumery training. It is equipped with advanced technology including a semi-industrial production robot and evaluation booths for various scent categories.
The center serves as an extension of IFF's Atelier du Perfumeur in Grasse and Shanghai Perfumery Art Studio, focusing on creating innovative fragrance solutions for the region's unique consumer demands in fine fragrances, home, fabric, and beauty care products.
IFF (NYSE:IFF) has announced it will release its first quarter 2025 earnings results after market close on Tuesday, May 6, 2025. The management team will host a live webcast on Wednesday, May 7, 2025, at 9:00 a.m. ET to discuss results and outlook with investors.
Investors can access the webcast and accompanying slide presentation through the company's website at ir.iff.com. A recorded version will be available for those unable to attend the live event.
IFF (NYSE: IFF) announced the consolidation of its Mexico operations at a new site in Mexico City's Tecnoparque business complex. The relocation will start with the Global Business Services Center and is expected to complete by 2026. The new facility will accommodate up to 650 employees across Health & Biosciences, Scent, Taste, and Food Ingredients divisions.
The strategic move includes laboratories for product creation, testing, R&D, and business services. The Tecnoparque complex features 50,000 square meters of green space, solar power generation, and advanced water management systems. IFF's existing Tlalnepantla facilities will continue operating as a strategic production site for Scent and Taste business units.
IFF (NYSE: IFF) has unveiled its new Citrus Innovation Center in Lakeland, Florida, in partnership with Florida Polytechnic University. The 30,000 square foot facility features state-of-the-art capabilities in botanical research, processing, analytics, and product creation for scent and taste applications.
The center includes advanced technologies like a 360-degree digital immersion room and focuses on applications in food and beverage, fine fragrance, body care, and fabric & home care. Supporting approximately 40 jobs, the facility emphasizes sustainability with LEED silver certification and a solar array system meeting its entire power demand.
The center demonstrates IFF's commitment to innovation and external partnerships, offering customers rapid product development capabilities, innovative citrus applications, and advanced product testing. Located on Florida Polytechnic University's campus, the facility provides direct access to industry experts and academia while featuring on-site prototyping capabilities for customized solutions.
IFF Pharma Solutions has launched Low Nitrite METHOCEL™ HPMC, a specialized range of cellulose ethers designed to reduce nitrosamine formation risk in pharmaceutical dosages. The innovative product maintains nitrite levels at or below 200 parts per billion, verified through validated 2D ion chromatography with mass spectrometry testing for each batch.
The new product line offers the same reliability and performance as standard METHOCEL™ while addressing industry concerns about nitrosamine risk mitigation. Through enhanced process controls and analytical science, the company ensures minimal nitrite content, making it suitable for applications where low nitrite levels are crucial.
Every batch receives a nitrite test result on the certificate of analysis, demonstrating IFF's commitment to quality and safety standards in pharmaceutical manufacturing.
IFF (NYSE: IFF) has launched its Science of Performance program, a new scientific approach to fragrance creation that enhances scent design efficiency and precision. The program combines decades of measured data with proprietary AI capabilities and advanced expertise across various applications.
The initiative focuses on three key scientific tracks: Fragrance Engineering using AI-driven consumer insights, Sustainable Fragrance Delivery Systems exploring technologies like fragrance encapsulation, and Additive Materials for enhancing scent profiles. These tracks power two platforms: IFF SCENT+ for optimizing fragrance intensity and IFF CTRL+D™ for malodor control.
IFF (NYSE:IFF) and Kemira have announced the formation of Alpha Bio, a joint venture focused on commercial-scale production of renewable biobased materials. The venture involves a €130 million investment, with production scheduled to begin in late 2027 at IFF's biorefinery in Kotka, Finland.
The facility will convert up to 44,000 MT of plant sugars into bioproducts, including high-performance biopolymers for home and personal care and industrial applications. The production will utilize IFF's proprietary Designed Enzymatic Biomaterial™ (DEB) platform technology, which creates biobased materials using plant-based sugars and enzymes under mild process conditions.
The joint venture will operate independently and is expected to create approximately 30 direct new jobs in the Kotka area, with additional employment during construction. The facility will manufacture specific DEB technology-enabled products exclusively for IFF and Kemira's use.
IFF (NYSE:IFF) Pharma Solutions will showcase its innovative excipient technologies at CPHI Japan 2025, taking place April 9-11 at Tokyo Big Sight. The company will highlight three key product lines:
1. Oral Disintegrating Tablet (ODT) Solutions, featuring Ac-Di-Sol® super disintegrant for rapid dissolution
2. Controlled Release Portfolio, including METHOCEL™ HPMC, ETHOCEL™ Ethylcellulose for water-resistant coatings, and POLYOX™ Polyethylene Oxide for high-swell matrices
3. Low-Nitrite Solutions, including Avicel® PH LN and Low Nitrite METHOCEL™, designed to reduce nitrosamine formation risks in oral solid dosages and meet Japan's regulatory standards
FAQ
What is the current stock price of International Flavors&Fragranc (IFF)?
What is the market cap of International Flavors&Fragranc (IFF)?
